Fig. 5
From: In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Ex vivo stimulation of whole blood from upadacitinib or placebo dosed healthy volunteers. Whole blood was drawn 1 h post upadacitinib or tofacitinib dose and stimulated with IL-6 (A) or IL-7 (B)